Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. specializes in the development of innovative genetic medicines aimed at transforming the treatment of cancer and other serious diseases through its proprietary drug discovery platform. Founded in 2012 and headquartered in Cambridge, US, Syros Pharmaceuticals, Inc. focuses on genetic medicines that target the underlying causes of disease.

The company has undergone significant growth, raising USD 130. 00 mn in a PIPE funding round led by various investors including Adage Capital Management and Bain Capital Life Sciences, with a total amount raised of USD 21. 83 mn across 11 deals. Richard Young, who has a background in biotech entrepreneurship, is the founder.

Syros Pharmaceuticals is dedicated to developing targeted medicines that address the root causes of serious diseases, particularly in oncology. Their primary offerings include therapeutic candidates that are in various stages of clinical development, aimed at enhancing patient outcomes. The company’s solutions cater to healthcare providers and research institutions in North America and Europe, with an expansion into the Asia-Pacific market to meet increasing demand for innovative therapies. In the most recent year of 2022, Syros Pharmaceuticals reported revenue of USD 14.

88 mn, with an EBITDA loss of USD 131. 97 mn for the same year. Their revenue model focuses on partnerships and collaborations that lead to the advancement of their proprietary therapies. Looking ahead, Syros Pharmaceuticals plans to utilize its recent funding from the PIPE round completed on January 19, 2021, to support the ongoing clinical trials and develop new therapeutic candidates.

The company aims to expand its product pipeline with several new drug candidates expected to enter clinical stages in the next few years. Furthermore, they are targeting expansion into international markets, specifically in Europe and Asia-Pacific, to leverage growing healthcare needs and enhance their global footprint.